This trial assessed the safety of treating patients afflicted by advanced tumours with MNRP1685A together with Bevacizumab, a humanised monoclonal antibody that inhibits VEGF and has been approved for the treatment of several types of cancer. Here, VEGFA is linked to neoplasm.